UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib
Tweet Content
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors:
- RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz.
- avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off